FRM
FULC icon

Fox Run Management’s Fulcrum Therapeutics FULC Stock Holding History

Fox Run Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Buy
+56,446
New +$343K 0.03% 802
2026
Q1 		– Sell
-25,568
Closed -$289K – 1014
2025
Q4 		$289K Sell
25,568
-25,223
-50% -$257K 0.04% 705
2025
Q3 		$467K Buy
+50,791
New +$367K 0.07% 521

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fox Run Management's FULC Position: Q2 2026 in Review

Fox Run Management opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 56,446 shares worth $207K. The stake represents 0.03% of the portfolio and ranks #802 among its holdings. This is a return to the name: Fox Run Management previously reported a position in FULC as recently as Q4 2025.

Fox Run Management first reported a position in FULC in Q3 2025 and has held it in 3 quarters since. The position peaked at $467K in Q3 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Fox Run Management held 56,446 shares of Fulcrum Therapeutics worth $207K as of Q2 2026.
  • Fulcrum Therapeutics was a new Fox Run Management position in Q2 2026.
  • Fulcrum Therapeutics made up 0.03% of Fox Run Management's portfolio in Q2 2026, its #802 holding.
  • Fox Run Management first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Fox Run Management's Fulcrum Therapeutics position peaked at $467K in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.